Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
GuideUpdated Report an error

What a $4 Million Gene Therapy Actually Costs a Family in 2026

US gene therapies now list at up to $4.25 million, and 2 have left the US market for commercial reasons. Families almost never pay the list price, though. The 2026 price list, what commercial insurance, Medicare and Medicaid leave families to pay, how to appeal a denial, and the support programs that handle travel and paperwork.

A young patient with glasses and an oxygen tube rests in a hospital bed beside a bank of monitors.

The FDA approved Fayuvi for Sanfilippo syndrome type A on September 17, 2026, and Ultragenyx set its list price at $3.95 million (BioSpace, 2026), which puts it level with Kebilidi and just behind Lenmeldy, which at $4.25 million has the highest US list price of any medicine (ICER, 2025).

Numbers like that are real, and they shape which therapies survive. They are also not the number a family ends up paying. This guide separates the two: what gene therapies cost the health system, and what it takes for a patient to actually receive one.

Gene Therapy Prices in 2026, From $500,000 to $4.25 Million

Every gene therapy below is a one-time treatment. The price is the US list price, called the wholesale acquisition cost, before the confidential discounts and rebates that insurers negotiate. Most companies announce their price at approval; a few, like PTC for Kebilidi, do not, and the figure comes out later through a company spokesperson or pricing databases.

US list price per patient, in millions of dollars
One-time treatments, checked November 3, 2026. List prices before confidential discounts. Lenmeldy and Kebilidi from ICER's 2025 launch price report; Zevaskyn, Itvisma and Encelto from ICER's 2026 report, which does not say whether Encelto's price is per eye; Fayuvi as reported by BioSpace; Genglycos as reported by MedCity News; others from company releases and trade press listed in the sources. Kresladi (LAD-I), Waskyra (Wiskott-Aldrich syndrome) and Voceryq (recurrent respiratory papillomatosis) have no announced US price, and Regeneron provides Otarmeni, for OTOF-related hearing loss, free in the US. Papzimeos, also for recurrent respiratory papillomatosis, is given 4 times over 12 weeks at $115,000 a dose, about $460,000 in all (FDA label; ICER, 2026), so it is not shown as a one-time price. Roctavian ($2.9 million) and Beqvez ($3.5 million) are no longer sold.
List price
Lenmeldy
metachromatic leukodystrophy
4.25M
Fayuvi
Sanfilippo syndrome type A
Approved Sept 2026
3.95M
Kebilidi
AADC deficiency
3.95M
Hemgenix
hemophilia B
3.5M
Elevidys
Duchenne, walking patients 4 and older
3.2M
Zevaskyn
recessive dystrophic EB
3.147M
Lyfgenia
sickle cell disease
3.1M
Skysona
cerebral adrenoleukodystrophy
3M
Zynteglo
beta-thalassemia
2.8M
Genglycos
glycogen storage disease Ia
Approved Aug 2026
2.7M
Itvisma
SMA, age 2 and older
2.59M
Casgevy
sickle cell, beta-thalassemia, age 2 and older
2.2M
Zolgensma
SMA, under age 2
2.125M
Luxturna
RPE65 retinal disease
0.85M
Encelto
macular telangiectasia type 2, eye implant
0.5M

Manufacturers justify these prices by arguing that a single infusion replaces a lifetime of care, such as years of factor replacement for hemophilia B or repeated spinal injections for spinal muscular atrophy. The Institute for Clinical and Economic Review (ICER), an independent group that estimates what a drug's benefit is worth, has usually come in below the list price, sometimes only slightly. Its 2023 review of the 2 sickle cell disease gene therapies shows how far apart 2 treatments for the same disease can sit.

Casgevy, sickle cell disease
About 7% above ICER's top estimate
ICER's health-benefit price benchmark for a sickle cell gene therapy was $1.35 million to $2.05 million. Casgevy launched at $2.2 million (ICER, 2023; CMS).
Lyfgenia, sickle cell disease
About 51% above ICER's top estimate
Against the same $1.35 million to $2.05 million fair value range, Lyfgenia launched at $3.1 million (ICER, 2023; CMS).

Who Pays for Gene Therapy: Insurance, Medicaid and the Out-of-Pocket Cap

For a family with commercial insurance, the question is coverage, not cost. Once an insurer approves a gene therapy, the family pays up to the plan's deductible and coinsurance and then stops at the out-of-pocket maximum. With a bill this size, a family generally reaches that ceiling quickly. Manufacturer copay programs, where a family qualifies, can cover much of the rest.

Getting to yes is slower. Insurers write a coverage policy for each new therapy. A Tufts Medical Center review of cell and gene therapy policies from 18 of the largest US commercial insurers found that about half added requirements beyond the FDA label, such as extra clinical or genetic criteria, although most of those matched who had been studied in the trials (Chambers et al., JAMA, 2025). New approvals can also sit with no policy at all: about 5 months after Kebilidi's approval, half of the 18 large commercial plans ICER checked still had no public coverage policy for it (ICER, 2025). No published study reliably measures how long prior authorization takes for gene therapy, so be wary of anyone quoting a precise number of weeks.

Medicaid and the CMS Cell and Gene Therapy Access Model

Medicaid generally must cover FDA-approved drugs from makers that take part in its rebate program, but states have wide latitude over the rules around them. For sickle cell disease, the federal government stepped in. Under the Cell and Gene Therapy Access Model, the Centers for Medicare & Medicaid Services (CMS) negotiated one set of outcomes-based terms for Casgevy and Lyfgenia on behalf of the states. If a treated patient does worse than expected, the manufacturer pays part of the cost back.

As of CMS's latest update, 32 states plus Washington, D.C. and Puerto Rico take part, covering about 84% of people with sickle cell disease on Medicaid. The model applies to sickle cell only for now. On October 27, 2026 CMS said it will add therapies for other conditions and will invite manufacturers to apply in the coming months, without naming any (CMS, 2026). Until then, a Medicaid family seeking gene therapy for hemophilia, SMA or Duchenne still goes through their own state's process.

Free email alert

Want to know the day the FDA decides on a rare disease treatment?

One email per decision, approvals and rejections alike, with what it means in plain language.

One email per FDA decision, the day it is announced. Some weeks have none and a busy week can have a few. Stop anytime. We never share your email. Privacy policy

Gene Therapy and Medicare, Including People Under 65 on Disability

Medicare matters more than many families expect, because it covers adults on disability as well as people over 65. About 7 million of Medicare's 68 million enrollees are under 65 (KFF, 2025). Most of them qualified after receiving Social Security disability benefits for 24 months (CMS). People with ALS qualify as soon as their disability benefits start, and people with kidney failure can qualify through dialysis or a transplant.

Children almost never have Medicare, so it rarely touches Zolgensma, Elevidys or Skysona. It does reach adults getting Hemgenix for hemophilia B, or Casgevy, Lyfgenia or Zynteglo for sickle cell disease or beta-thalassemia. A Congressional Budget Office report cites estimates that about 11% of people with sickle cell disease are covered by Medicare (CBO, 2024).

What a person on Original Medicare pays depends on where the therapy is given. Casgevy, Lyfgenia and Zynteglo require chemotherapy to clear the bone marrow first, which means a hospital stay. Part A covers that stay after a deductible of $1,736 in 2026, with $0 a day for days 1 through 60 (Medicare.gov). Doctors' services during the stay are billed separately under Part B at 20%.

Treatment given in a hospital outpatient department falls under Part B. Part B normally charges 20%. In most hospitals, though, Medicare caps the copay for a single outpatient service at the Part A deductible of $1,736 in 2026 (42 CFR 419.41). The $283 Part B deductible and 20% of the doctor's fees come on top. Critical access hospitals are the exception. These small rural hospitals have a special Medicare status, and Medicare.gov warns that the copay there can exceed the deductible.

Where each therapy is given varies by hospital, so the treatment center's financial counselor is the person who can say which of these rules applies. Most Medigap supplement plans pay the Part B coinsurance in full and also pay the Part A deductible. Plan A pays none of that deductible and Plan M pays half of it. Plans K and L pay part of the costs and carry 2026 out-of-pocket limits of $8,000 and $4,000 (Medicare.gov). People under 65 can find Medigap harder to buy, because federal law does not require insurers to sell it to them and the rules vary by state.

What a patient owes for a covered gene therapy in 2026, by type of coverage. Trial Friend lined up the 2026 cost-sharing rules from HealthCare.gov, Medicare.gov, federal regulations, CMS and KFF on November 3, 2026. Doctors' fees, travel and lodging are separate.
CoverageMost the patient owes for the therapy itselfSource
Marketplace or job-based planThe plan's out-of-pocket maximum, up to $10,600 for 1 person or $21,200 for a family on 2026 Marketplace plansHealthCare.gov
Medicare AdvantageThe plan's in-network maximum, at most $9,250 in 2026; the average plan's limit is $5,421KFF, 2026
Original Medicare, hospital stayThe $1,736 Part A deductible for days 1 through 60Medicare.gov
Original Medicare, hospital outpatientCopay capped at $1,736 per service in most hospitals, plus the $283 Part B deductible; no cap at critical access hospitals42 CFR 419.41; Medicare.gov
Original Medicare with MedigapMost plans pay the Part B coinsurance and the Part A deductible; Plans A, K, L and M pay less, and few plans pay the Part B deductibleMedicare.gov
Qualified Medicare Beneficiary programProviders may not bill Medicare deductibles or coinsuranceCMS

The yearly limit resets on January 1st for Marketplace plans and Medicare Advantage, and at the start of the plan year for job-based plans. The Part B deductible also resets each January, while the Part A deductible applies to each benefit period rather than each year. Therapies made from a patient's own cells can cross that line, because manufacturing Casgevy from the collected cells may take up to 6 months (Vertex, Casgevy patient information). When the collection falls in one year and the hospital stay in the next, a family can owe cost sharing in both years, up to each year's limit. The treatment center's financial counselor can map out how those costs are likely to fall.

CMS has already set some of the 2027 limits, with Marketplace and job-based plans capped at $12,000 for 1 person or $24,000 for a family (CMS, 2026). The Medigap Plan K and Plan L limits rise to $8,360 and $4,180 in 2027 (CMS, 2026). Medicare's 2027 deductibles had not been published when Trial Friend checked on November 3, 2026, and CMS usually announces them in November.

People with low income may qualify for the Qualified Medicare Beneficiary program, whose 2026 income limit is $1,350 a month for 1 person in most states. Hospitals and doctors may not bill its members for Medicare deductibles, coinsurance or copays, even when Medicaid pays nothing (CMS, 2025). Its sister program for slightly higher incomes pays only the Part B premium, not coinsurance.

Manufacturer copay cards generally exclude Medicare, as the terms for Zolgensma and Elevidys state, and CSL limits Hemgenix copay support to commercially insured patients. Independent charity funds can help Medicare patients, but they open and close as money comes in. The HealthWell Foundation runs a sickle cell fund that lists Casgevy and Lyfgenia and accepts Medicare patients. That fund was closed when Trial Friend checked on November 3, 2026.

If Insurance Denies Gene Therapy, How the Appeal Works

A denial is rarely the last word, though few families push back. KFF found that fewer than 1% of denied in-network claims on HealthCare.gov plans in 2024 were appealed (KFF, 2026). When people did appeal, it often worked. In large insurers' own 2025 reports, 43% of appealed prior authorization denials were overturned on Marketplace plans, 47% in Medicaid managed care and 67% in Medicare Advantage (KFF, 2026).

For a commercial plan, the family can file an internal appeal within 180 days of the denial. A request for treatment not yet given gets a decision within 30 days, or within 72 hours if waiting could seriously harm the patient (Department of Labor). If the plan still says no, an independent external review can be requested within 4 months, and the insurer must accept the reviewer's decision (HealthCare.gov).

In 2026, 71% of covered workers were in self-funded job-based plans, which follow federal appeal rules enforced by the Department of Labor (KFF, 2026). Medicaid managed care plans take an appeal within 60 days, and a state fair hearing can follow. Original Medicare has a separate appeal process with 5 levels, starting with the contractor that processed the claim, while a Medicare Advantage appeal starts with the plan.

A strong appeal usually includes a letter of medical necessity from the specialist and the test results that match the FDA label. It can also ask for a peer-to-peer call between the specialist and the insurer's doctor. The manufacturer's support program and the treatment center often help write it. By Novartis's own count, about 98% of children under 2 with SMA whose insurance decision was known were approved for Zolgensma between 2019 and 2021. That figure includes approvals won on appeal.

Gene Therapy Patient Support Programs and Travel Help

Gene therapies are given only at a small number of qualified treatment centers, which often means a long trip and, for cell-based therapies like Casgevy or Lyfgenia, weeks near the hospital. Every manufacturer runs a support program with a case manager who checks insurance, handles prior authorization paperwork and, for most programs, helps with travel and lodging for eligible patients. These programs are free to use, and most of their help does not depend on income, though copay assistance is usually limited to commercially insured patients and excludes Medicare.

Zolgensma and Itvisma (Novartis)
Novartis Patient Support. A case coordinator handles insurance and appeals, and eligible commercially insured patients can use copay assistance.
Casgevy (Vertex)
Vertex Connects. A care manager coordinates logistics, with travel and lodging help for eligible patients.
Hemgenix (CSL Behring)
HEMGENIX Connect. A patient navigator and case manager, copay support for eligible commercially insured patients, and travel and logistics help.
Elevidys (Sarepta)
SareptAssist, at 1-888-727-3782, for logistics and insurance navigation.
Lenmeldy (Orchard, a Kyowa Kirin company)
Orchard Assist. Benefits checks, prior authorization help, out-of-pocket estimates, and a review of whether your plan covers travel and lodging.
Lyfgenia, Zynteglo and Skysona (Genetix, formerly bluebird bio)
Genetix CARES, formerly called my bluebird support. Travel and lodging, financial assistance and fertility preservation support.
Fayuvi and Genglycos (Ultragenyx)
UltraCare, with dedicated Gene Therapy Guides, at 888-756-8657.

Ask the treatment center's financial counselor as well. Centers that give gene therapy regularly have handled these approvals before and usually know which of your insurer's requirements trip families up.

Gene Therapy Warranties and Outcomes-Based Agreements

Because a one-time price is paid before anyone knows how long the benefit lasts, several companies promise money back if the therapy underdelivers. These deals are between the manufacturer and the insurer, so they protect the health system rather than the family directly, though they are meant to make insurers more willing to approve.

bluebird bio said in 2022 that it would refund up to 80% of Zynteglo's cost if a patient does not become and stay free of blood transfusions for up to 2 years. Hemgenix's maker, CSL Behring, has said it refunds a substantial but undisclosed share if a patient goes back on regular factor IX treatment within 4 years (Cell & Gene, 2023). Zolgensma launched with 5-year outcomes-based agreements and a pay-over-time option (Novartis, 2019), and pharmaphorum reported in April 2025 that Zevaskyn's price includes a partial refund if a patient needs more treatment.

Gene Therapies Withdrawn for Commercial Reasons, From Beqvez to Roctavian

A high price only matters if someone pays it, and 2 gene therapies have now left the US market for commercial reasons rather than safety ones. Pfizer stopped selling Beqvez for hemophilia B in February 2025, citing the limited interest patients and their doctors had shown in hemophilia gene therapies, and BioPharma Dive reported that Pfizer had not disclosed any Beqvez sales (BioPharma Dive, 2025). BioMarin withdrew Roctavian for hemophilia A in 2026 after it was unable to find a qualified buyer, said the decision was not related to the therapy's efficacy or safety, and told the hemophilia community it would keep the therapy available to US patients through the end of May (BioMarin, 2026; National Bleeding Disorders Foundation, 2026). Earlier, bluebird bio pulled Zynteglo and Skysona from Europe in 2021 after a pricing dispute in Germany. Supply can also stall without a withdrawal, as it did when CSL reported a global Hemgenix stockout in March 2026. In July CSL said 22 people worldwide had been treated since limited supply resumed (CSL, 2026).

bluebird itself, whose therapies won FDA approval and whose market value once topped $11 billion, agreed in February 2025 to sell itself to private equity firms Carlyle and SK Capital for less than $30 million (STAT, 2025) and now operates as Genetix Biotherapeutics. Its Lyfgenia, Zynteglo and Skysona remain available in the US, though the FDA narrowed Skysona's label in August 2025 after blood cancers were diagnosed in 10 of 67 trial patients (FDA, 2025).

For patients, the lesson from these withdrawals is practical. A therapy approved for your condition is only an option while someone is still making and selling it, and people already treated keep their follow-up care: BioMarin, for one, has said it will continue monitoring Roctavian patients and honoring its outcomes-based agreements with payers.

Get the next update by email

One email when trials change or decisions land for the conditions you care about. No newsletter, no spam.

You'll get:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site

Questions Families Ask About Gene Therapy Costs

How much does gene therapy cost in 2026?

US list prices for one-time gene therapies range from $500,000 (Encelto) to $4.25 million (Lenmeldy), and most fall between $2 million and $4 million. Fayuvi and Kebilidi are reported at $3.95 million. These are list prices before confidential discounts, and they are generally paid by insurers or Medicaid, not by families.

Will my insurance cover gene therapy?

Most large insurers cover FDA-approved gene therapies for patients who meet their policy's criteria, but many policies add requirements beyond the FDA label, and very new approvals may not have a policy yet. The manufacturer's patient support program and the treatment center's financial counselor can check your plan and handle prior authorization for you.

How much will I pay out of pocket for gene therapy?

With insurance, your share is limited by your plan's yearly out-of-pocket maximum. For 2026 Marketplace plans that cap is $10,600 for an individual and $21,200 for a family. Manufacturer copay programs may reduce it further for eligible commercially insured patients. Travel and lodging are separate costs, and most manufacturer programs help with them.

Does Medicaid cover gene therapy for sickle cell disease?

In most states, yes. Under the CMS Cell and Gene Therapy Access Model, 32 states plus Washington, D.C. and Puerto Rico cover Casgevy and Lyfgenia for Medicaid patients under outcomes-based terms negotiated by CMS, reaching about 84% of people with sickle cell disease on Medicaid. Other states handle coverage through their own Medicaid process.

Does Medicare cover gene therapy?

Medicare can cover an FDA-approved gene therapy that is reasonable and necessary for the patient, under Part A during a hospital stay or Part B for outpatient care. Original Medicare has no yearly out-of-pocket cap, but in most hospitals its copay for the therapy is held to about the $1,736 Part A deductible in 2026, plus the $283 Part B deductible for outpatient care and doctors' fees. Most Medigap plans pay much of that, while a Medicare Advantage plan uses its own copays up to its yearly limit, which can be higher.

Can I appeal if insurance denies gene therapy?

Yes, plans that are not grandfathered under the Affordable Care Act must offer an internal appeal and then an independent external review whose decision the insurer must follow. The federal external review process is free, and a state process or contracted reviewer can charge at most $25 (HealthCare.gov). If a plan breaks the appeal rules in more than a minor way, the family can go straight to external review (Department of Labor).

What is the most expensive drug in the world?

In the United States, the highest list price is Lenmeldy, a one-time gene therapy for metachromatic leukodystrophy, at $4.25 million. Fayuvi and Kebilidi follow at $3.95 million each.

If you are weighing a clinical trial instead of an approved therapy, trial sponsors pay for the treatment itself, and many cover travel too. Our guide to the hidden costs of clinical trials walks through what they usually do and do not cover.

Know someone this would help?

Sources

An Update on HEMGENIX Availability
CSL · 2026-03-17
Zolgensma and Itvisma CopayAssist eligibility
Novartis
SareptAssist
Sarepta Therapeutics
HEMGENIX patient access and copay support overview
CSL Behring
42 CFR 438.402, Medicaid managed care appeals
U.S. Government Publishing Office
Appeals in Original Medicare
Medicare.gov
2026 Launch Price and Access Report
Institute for Clinical and Economic Review · 2026-10-20
Health Policy 101: Medicare
KFF · 2025-10-08
2026 Medicare Parts A & B Premiums and Deductibles
Centers for Medicare & Medicaid Services · 2025-11-14
Inpatient hospital care
Medicare.gov
Outpatient hospital services
Medicare.gov
42 CFR 419.41, Calculation of national beneficiary copayment amounts
Electronic Code of Federal Regulations
Medicare Advantage Out-of-Pocket Limits: Variation and Trends
KFF · 2026-05-28
Compare Medigap plan benefits
Medicare.gov
Original Medicare (Part A and B) eligibility and enrollment
Centers for Medicare & Medicaid Services
How Increased Use of Gene Therapy Treatment for Sickle Cell Disease Could Affect the Federal Budget
Congressional Budget Office · 2024-12
Medicare Savings Programs
Medicare.gov
Prohibition on Billing Qualified Medicare Beneficiaries (MLN7936176)
Centers for Medicare & Medicaid Services · 2025-09
Cell and Gene Therapy Access Model to add new therapies
Centers for Medicare & Medicaid Services · 2026-10-27
Sickle Cell Disease fund
HealthWell Foundation
Claims Denials and Appeals in ACA Marketplace Plans in 2024
KFF · 2026-03-24
Prior Authorization Metrics Provide New Insights Into Insurer Practices
KFF · 2026-08-13
Filing a Claim for Your Health Benefits
U.S. Department of Labor
External review
HealthCare.gov
2026 Employer Health Benefits Survey
KFF · 2026-10-22
Zolgensma prior authorization and appeals guide
Novartis
An Update on HEMGENIX Supply and Patient Access
CSL · 2026-07-24
FDA approves new safety warning and revised indication limiting use of Elevidys
U.S. Food and Drug Administration · 2025-11-14
Casgevy
U.S. Food and Drug Administration
Otarmeni approved by FDA; Regeneron to provide Otarmeni for free in the U.S.
Regeneron (GlobeNewswire) · 2026-04-23
FDA approves Precigen's Papzimeos
PharmaVoice · 2025-09-12
2025 Launch Price and Access Report
Institute for Clinical and Economic Review · 2025-10
Ultragenyx wins FDA greenlight for first Sanfilippo therapy, priced at nearly $4M
BioSpace · 2026-09
Ultragenyx Gene Therapy Becomes First FDA-Approved Treatment for Ultra-Rare Disease
MedCity News · 2026-08-20
FDA approves first gene therapy for pediatric patients with Sanfilippo syndrome type A
U.S. Food and Drug Administration · 2026-09-17
Premium Adjustment Percentage, Maximum Annual Limitation on Cost Sharing and Related Parameters for the 2027 Benefit Year
Centers for Medicare & Medicaid Services · 2026-01-29
Out-of-Pocket Limits for Medigap Plans K & L for Calendar Year 2027
Centers for Medicare & Medicaid Services · 2026-10
Casgevy patient information
Vertex Pharmaceuticals
Out-of-pocket maximum/limit
HealthCare.gov
Cell and Gene Therapy Access Model: Frequently Asked Questions
Centers for Medicare & Medicaid Services
ICER publishes final evidence report on gene therapies for sickle cell disease
Institute for Clinical and Economic Review · 2023
ICER publishes final evidence report on gene therapy for metachromatic leukodystrophy
Institute for Clinical and Economic Review · 2023
Variation in US Commercial Health Plan Coverage Restrictions for Cell and Gene Therapies
JAMA · 2025-09-29
bluebird bio Announces U.S. Commercial Infrastructure to Enable Patient Access to ZYNTEGLO
bluebird bio (Business Wire) · 2022-08-17
CSL's Hemgenix shows durable benefit, a new future for gene therapy in hemophilia B
Cell & Gene
AveXis announces innovative Zolgensma gene therapy access programs for US payers and families
Novartis · 2019-05
Novartis scores FDA approval for new version of SMA gene therapy, prices at $2.59M
Fierce Pharma · 2025-11
Abeona prices rare cell disorder gene therapy at $3.1M
pharmaphorum · 2025-04
Pfizer halts sales of hemophilia gene therapy Beqvez
BioPharma Dive · 2025-02
BioMarin voluntarily withdraws Roctavian from the market
BioMarin Pharmaceutical · 2026-02-23
BioMarin Pulls ROCTAVIAN Hemophilia A Gene Therapy from U.S. Market
National Bleeding Disorders Foundation · 2026-02-26
bluebird bio sells itself to Carlyle, SK Capital for less than $30 million
STAT · 2025-02-21
FDA approves required labeling changes for increased risk of hematologic malignancy following treatment with Skysona
U.S. Food and Drug Administration · 2025-08
bluebird to withdraw gene therapies from Europe
BioPharma Dive · 2021-10
TaggedGuideGene TherapyHealthcare AccessRare Disease Policy

More on Trial Friend

DisclosureThe author has done professional work for companies whose products are discussed in this article. No company reviewed, paid for or had any input into it.